We serve Chemical Name:3-Chloro-5-carboxy-2-methoxypyridine CAS:884494-85-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Chloro-5-carboxy-2-methoxypyridine
CAS.NO:884494-85-3
Synonyms:5-chloro-6-methoxypyridine-3-carboxylic acid;3-Chloro-5-carboxy-2-methoxypyridine;5-Chloro-6-methoxynicotinic acid;5-Choro-6-methoxynicotinic acid;3-Pyridinecarboxylic acid, 5-chloro-6-methoxy-
Molecular Formula:C7H6ClNO3
Molecular Weight:187.580
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:296.7±35.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.567
PSA:59.42000
Exact Mass:187.003616
LogP:2.10
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-chloro-6-methoxypyridine-3-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Pyridinecarboxylic acid, 5-chloro-6-methoxy- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Chloro-6-methoxynicotinic acid Use and application,3-Pyridinecarboxylic acid, 5-chloro-6-methoxy- technical grade,usp/ep/jp grade.
Related News: Lonza’s Nansha site is fully integrated within the company’s global manufacturing network. Scientists and engineers based in Nansha focus on API development and manufacturing for customers around the globe. 2-[(3-chloro-phenylcarbamoyloxy)-methyl]-isothiazol-3-one manufacturers For category of products which involve fermentation technologies, incentive is 20 per cent of the approved sales price. The government has put a cap of Rs. 10 crore per product per annum for five years. This is a seven year scheme from 2023-24 going up to 2029-30. N-(3-(diisobutylamino)propyl)-2-oxo-6-(piperidin-1-ylsulfonyl)-1,2-dihydroquinoline-4-carboxamide suppliers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. 2,5,N-trimethyl-p-phenylenediamine vendor & factory.
